DRW Securities’s AbbVie ABBV Stock Holding History

DRW Securities’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,200	Closed	-$377K	–	545
2024 Q2	$377K	Buy	2,200 +1,000	+83%	+$166K	0.01%	368
2024 Q1	$219K	Buy	+1,200	New	+$207K	0.01%	326

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DRW Securities's ABBV Position: Q2 2026 in Review

DRW Securities sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 1,353 shares — an estimated $293K sold.

DRW Securities first reported a position in ABBV in Q1 2016 and held it in 20 quarters. The position peaked at $8.13M in Q1 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

DRW Securities reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 1,353 AbbVie shares in Q2 2026, an estimated $293K.
DRW Securities first reported a position in AbbVie in Q1 2016 and held it in 20 quarters.
DRW Securities's AbbVie position peaked at $8.13M in Q1 2025.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.